Synthesis and secretion of plasminogen activator inhibitor-1 by human preadipocytes

被引:53
|
作者
Crandall, DL
Quinet, EM
Morgan, GA
Busler, DE
McHendry-Rinde, B
Kral, JG
机构
[1] Wyeth Ayerst Labs Inc, Res, Radnor, PA USA
[2] Downstate Med Ctr, Dept Surg, Brooklyn, NY 11203 USA
来源
关键词
D O I
10.1210/jc.84.9.3222
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To further investigate the role of plasminogen activator inhibitor-1 (PAI-1) in adipose tissue physiology, the production and regulation of PAI-1 was determined in primary cultures of human preadipocytes. When expressed as production per cell and cultured under identical conditions, human preadipocytes from both visceral (omental) and sc depots of lean and obese individuals released significant, yet similar, amounts of PAI-1 protein into the conditioned medium. High steady-state PAI-1 messenger RNA (mRNA) concentrations were observed in visceral and sc preadipocytes, with the relative level of expression equivalent to beta-actin mRNA. Tumor necrosis factor alpha significantly decreased PAI-1 production in a concentration-dependent manner in both visceral and sc cultures, whereas transforming growth factor beta significantly elevated PAI-1 production, but only in se preadipocytes from obese individuals. Addition of insulin had no effect on antigen levels in conditioned medium of preadipocyte cultures. Stimulation of the preadipocyte cultures with a defined medium resulted in differentiation to the adipocyte phenotype, as determined by flow cytometric analysis, verifying the cultures as human preadipocyte. These studies are the first to observe significant PAI-1 mRNA expression and protein production in primary cultures of a human adipose tissue cellular component, and they suggest that nascent adipocytes contribute significantly to the elevated plasma PAI-1 observed in obesity.
引用
收藏
页码:3222 / 3227
页数:6
相关论文
共 50 条
  • [21] Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue
    Van Harmelen, V
    Wahrenberg, H
    Eriksson, P
    Arner, P
    THROMBOSIS AND HAEMOSTASIS, 2000, 83 (02) : 304 - 308
  • [22] Plasminogen activator inhibitor-1 and diabetic nephropathy
    Lee, HB
    Ha, H
    NEPHROLOGY, 2005, 10 : S11 - S13
  • [23] Biochemical properties of plasminogen activator inhibitor-1
    Dupont, Daniel Miotto
    Madsen, Jeppe Buur
    Kristensen, Thomas
    Bodker, Julie Stove
    Blouse, Grant Ellsworth
    Wind, Troels
    Andreasen, Peter Andre
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2009, 14 : 1337 - 1361
  • [24] Plasminogen activator inhibitor-1 in vascular thrombosis
    Westrick, Randal J.
    Eitzman, Daniel T.
    CURRENT DRUG TARGETS, 2007, 8 (09) : 996 - 1002
  • [25] Pleiotropic functions of plasminogen activator inhibitor-1
    Lijnen, HR
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) : 35 - 45
  • [26] Plasminogen activator inhibitor-1 and haemostasis in obesity
    Mutch, NJ
    Wilson, HM
    Booth, NA
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2001, 60 (03) : 341 - 347
  • [27] Plasminogen activator inhibitor-1 in the pathogenesis of asthma
    Cho, SH
    Ryu, CH
    Oh, CK
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2004, 229 (02) : 138 - 146
  • [28] PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND ATHEROTHROMBOSIS
    JUHANVAGUE, I
    ALESSI, MC
    THROMBOSIS AND HAEMOSTASIS, 1993, 70 (01) : 138 - 143
  • [29] Plasminogen activator inhibitor-1 in cancer research
    Li, Sijing
    Wei, Xiaohui
    He, Jinyong
    Tian, Xuemei
    Yuan, Shengtao
    Sun, Li
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 105 : 83 - 94
  • [30] Structural investigations of plasminogen activator inhibitor-1
    Szabo, AG
    Abbott, G
    Luck, L
    Blouse, G
    Shore, J
    Perron, M
    BIOPHYSICAL JOURNAL, 2004, 86 (01) : 359A - 359A